Low-dose radiation before CAR T-cell therapy for lymphoma or myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether giving a low dose of radiation to the whole body before receiving CAR T-cell therapy helps the treatment work better for people with certain types of lymphoma or multiple myeloma that have come back or not responded to earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma (DLBCL) that did not respond to first treatment, came back within 12 months, or has returned after two or more treatments.
- Or you have multiple myeloma that has returned or not responded to at least one prior treatment, including a proteasome inhibitor and an immunomodulatory drug, and is refractory to lenalidomide.
- You are 18 years or older.
- You are generally able to care for yourself and are up and about more than half of your waking hours.
- Your organs are working well enough: adequate blood counts, kidney and liver function, and a heart ejection fraction above 40%.
- You have not had whole-body radiation or CAR T-cell therapy before.
- You do not have active infections (HIV, hepatitis B/C) or uncontrolled fungal/bacterial/viral infections.
- You do not have certain blood cancers or conditions like myelodysplastic syndrome or central nervous system involvement.
- If you could become pregnant, you must not be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving radiation and an oral antibiotic (vancomycin) before CAR-T therapy helps treat B-cell lymphoma more effectively. It is for people who are already scheduled to receive CAR-T treatment.
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
This trial adds a low dose of radiation to the entire body before CAR T cell therapy for patients with acute lymphoblastic leukemia. The goal is to see if this extra step helps the CAR T cells work better, without adding much extra discomfort.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
This trial tests a new two-step treatment: first a small dose of radiation (131I-Apamistamab) followed by specially designed immune cells (CAR-T cells) to fight your lymphoma. It is for people with DLBCL that has relapsed or not responded to standard therapy.
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
Hear when a new Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.